Outcome of allo-sct for chronic myelomonocytic leukemia

Access through your institution Buy or subscribe Chronic myelomonocytic leukemia (CMML) is a rare heterogeneous malignancy with an annual incidence of 13:100 000 occurring predominantly

>65 years of age. The phenotype varies from myelodysplastic to myeloproliferative features, and the clinical course is heterogeneous.1 Treatment strategies are expanding because of new

compounds, for example, lenalidomide2 or intensive chemotherapy for advanced stages,3 and increasing numbers of patients receive allogeneic haematopoietic SCT from related/unrelated donors

facilitated by reduced intensity conditioning (RIC).4 The design of guidelines based on the individual risk profiles is difficult in CMML,5 as its rare heterogenous presentation hampers the

evaluation of larger samples. To contribute to insights in the outcome of SCT in this rare disorder, we retrospectively analyzed 12 consecutive CMML patients receiving 13 allogeneic SCT at

the University of Hamburg, Germany, from January 2003 to June 2007. All 12 patients gave informed consent. Some patients were included in a previous study.6 One patient (no. 1) received two

allo-SCTs from two different unrelated donors. Eleven patients had unrelated donors (six HLA matched, five mismatched in the HLA-DQB1-alleles), and two received SCT from HLA-identical

siblings. All 13 transplants were performed with PBSCs (mean dose 7.65 × 106 CD34+/kg; range 3.9–11.34). The CMV status was the same in 12 donor/recipient pairs (Table 1). This is a preview

of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only

$21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Aul C, Giagounidis A, Germing U, Ganser A . Evaluating

the prognosis of patients with myelodysplastic syndromes. _Ann Hematol_ 2002; 81: 485–497. Article  CAS  Google Scholar  * Platzbecker U, Mohr B, von Bonin M, Schetelig J, Ehninger G,

Bornhauser M . Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. _Leukemia_ 2007;

21: 2384–2385. Article  CAS  Google Scholar  * Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L _et al_. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and

G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. _Ann Hematol_ 2004; 83: 498–503. Article  CAS  Google Scholar  * Deeg HJ, Shulman HM,

Anderson JE, Bryant EM, Gooley TA, Slattery JT _et al_. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. _Blood_ 2000; 95:

1188–1194. CAS  PubMed  Google Scholar  * Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Bienzen A _et al_. Allogeneic stem cell transplantation of adult chronic myelomonocytic

leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). _Br J Haematol_ 2002; 118: 67–73. Article  Google

Scholar  * Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG _et al_. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity

conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. _Ann Hematol_ 2003; 82: 336–342. Article  CAS  Google Scholar  * Schmid C, Schleuning M,

Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D _et al_. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and

reduced-intensity conditioning for allogeneic stem cell transplantation. _Blood_ 2006; 108: 1092–1099. Article  CAS  Google Scholar  * Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau

DA, Ansell SM _et al_. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. _Bone Marrow Transplant_ 2006; 37: 1003–1008. Article  CAS 

Google Scholar  * Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM _et al_. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. _Biol Blood Marrow

Transplant_ 2005; 11: 713–720. Article  Google Scholar  * Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T _et al_. Reduced-intensity conditioning followed by allogeneic

hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. _Biol Blood Marrow Transplant_ 2008; 14: 246–255. Article  Google

Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Interdisciplinary Clinic for Stem Cell Transplantation, University of Hamburg, Hamburg, Germany S Ocheni, N Kröger,

 T Zabelina, A R Zander & U Bacher * Department of Haematology and Immunology, University of Nigeria, Nsukka, Enugu Campus, Nigeria S Ocheni Authors * S Ocheni View author publications

You can also search for this author inPubMed Google Scholar * N Kröger View author publications You can also search for this author inPubMed Google Scholar * T Zabelina View author

publications You can also search for this author inPubMed Google Scholar * A R Zander View author publications You can also search for this author inPubMed Google Scholar * U Bacher View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to U Bacher. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Ocheni, S., Kröger, N., Zabelina, T. _et al._ Outcome of allo-SCT for chronic myelomonocytic leukemia. _Bone Marrow Transplant_ 43, 659–661 (2009).

https://doi.org/10.1038/bmt.2008.366 Download citation * Published: 10 November 2008 * Issue Date: April 2009 * DOI: https://doi.org/10.1038/bmt.2008.366 SHARE THIS ARTICLE Anyone you share

the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative